Open AccessA Pilot Study Embedding Clinical Pharmacists Within an Interprofessional Nephrology Clinic for the Initiation and Monitoring of Empagliflozin in Diabetic Kidney Disease
Author(s) -
Laura K. Triantafylidis,
Chelsea E. Hawley,
Christopher O Fagbote,
Jiahua Li,
Nicole Genovese,
Julie M. Paik
Publication year - 2019
Publication title -
journal of pharmacy practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.407
H-Index - 28
eISSN - 1531-1937
pISSN - 0897-1900
DOI - 10.1177/0897190019876499
Subject(s) - medicine , empagliflozin , clinical pharmacy , nephrology , kidney disease , disease , diabetes mellitus , type 2 diabetes , intensive care medicine , family medicine , pharmacy , endocrinology
The American Diabetes Association (ADA) recommends sodium-glucose cotransporter-2 (SGLT2) inhibitors as the second medication to be started, after metformin, for patients with chronic kidney disease (CKD). Sodium-glucose cotransporter-2 inhibitors may cause volume, blood pressure, and electrolyte disturbances; consequently, frequent monitoring and adjustments to other diabetes, blood pressure, and/or diuretic medications may be necessary.